![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Blackwell Publishing
E-ISSN: 1097-0142|120|23|3731-3737
ISSN: 0008-543X
Source: Cancer, Vol.120, Iss.23, 2014-12, pp. : 3731-3737
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical benefit of lovastatin consistent across risk groups
Inpharma, Vol. 1, Iss. 1264, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit–risk assessment: the use of clinical utility index
Expert Opinion on Drug Safety, Vol. 9, Iss. 2, 2010-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
OCs: benefits outweigh adverse effects for cancer risk
Reactions Weekly, Vol. 1, Iss. 1121, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefits of thrombolytics outweigh risk in diabetic patients
Inpharma, Vol. 1, Iss. 1377, 2003-01 ,pp. :